Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

This trial is testing a new CAR T cell therapy called TC011 — a treatment where a patient's own immune cells are genetically modified in the lab to target and destroy cancer cells — in people with large B-cell lymphoma that has come back or stopped responding to treatment. **You may be eligible if...** - You are 19 years or older - You have been diagnosed with large B-cell lymphoma that has returned or not responded to at least 2 prior treatments - You are in reasonably good health and have a life expectancy of at least 12 weeks - You have at least one measurable tumor - Your heart and organ function are adequate - You are able to undergo the cell collection process (leukapheresis) **You may NOT be eligible if...** - You have had prior CAR T cell therapy, gene therapy, or bone marrow transplant from a donor - You have active HIV, hepatitis B or C, or syphilis - You have cancer that has spread to the brain or spinal fluid - You have had major surgery in the past 4 weeks - You are pregnant or breastfeeding - Your disease is rapidly worsening Talk to your doctor to see if this trial is right for you.